Adverse events in patients treated with capecitabine as adjuvant chemotherapy after surgery for colorectal cancer - Countermeasures against hand-foot syndrome

Japanese Journal of Cancer and Chemotherapy

Volumn 37, Issue 9, 2010, Pages 1729-1733

  Suto, Takeshi ^a   Ishiyama, Koushiro ^a   Yabuki, Hiroshi ^a   Mori, Naoki ^a   Inoue, Koetsu ^a   Chiba, Masato ^a   Igawa, Akiko ^a   Watanabe, Toshihiro ^a   Fujimoto, Hiroto ^a   Suzuki, Yumi ^a   Sugawara, Makoto ^a   Saito, Tomomi ^a   Kobayashi, Yuka ^a   Matsuda, Mikiko ^a   Ikeda, Eiichi ^a   Sato, Toshihiko ^a   Iizawa, Hajime ^a  

^a Yamagata Prefectural Central Hospital   (Japan)

Author keywords

Capecitabine; Chemotherapy; Colorectal cancer; Hand foot syndrome

Indexed keywords

CAPECITABINE; HUMECTANT; PYRIDOXINE;

ADULT; AGED; AGRICULTURAL WORKER; ANTICOAGULATION; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER SURGERY; CLINICAL ARTICLE; COLORECTAL CANCER; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG SAFETY; HAND FOOT SYNDROME; HUMAN; INCIDENCE; MECHANICAL STIMULATION; MULTIPLE CYCLE TREATMENT; SIDE EFFECT;

EID: 79960774940     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Blum JL, Jones SE, Buzdar AU, et al: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17: 485, 1999.
2. Zuehlke RK: Erythematous eruption of palms and soles associated with mitomycin therapy. Dermatologica 148: 90-92, 1974.
3. Komamura H, Higashiyama M, Hashimoto K, et al: Three cases of chemotherapy-induced acral erythema. J Dermatol 22: 116-121, 1995.
4. Mortimer JE, Lauman MK, Tan B, et al: Pyridoxine treatment and prevention of hand-and-foot syndrome in patients receiving capecitabine. J Oncol Pharm Pract 9 (4): 161-166, 2003.
5. Diasio RB: Oral DPD-inhibitory fluoropyrimidine drugs. Oncology 14 (suppl 9): 19-23, 2000.
6. Arai K, Iwasaki Y, Kimura Y, et al: A patient with recurrent gastric cancer who developed TS-1 induced hand-foot syndrome. Gan to Kagaku Ryoho 30(5): 699-702, 2003.
7. Lamont EB and Schilsky RI: The oral fluoropyrimidines in cancer chemotherapy. Clin Cancer Res 5(9): 2289-2296, 1999.
8. Miwa M, Ura M, Nishida M, et al: Design of novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34: 1274-1281, 1998.
9. Vail DM, Chun R, Thamm DH, et al: Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using acanine model. Clin Cancer Res 4(6): 1567-1571, 1998.
10. Lassere Y and Paulo Hoff: Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs 8(suppl 1): 31-40, 2004.
11. Gressett SM, Stanford BL and Hardwicke F: Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract 12(3): 131-141, 2006.
12. Heo YS, Chang HM, Kim TW, et al: Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy. J Clin Pharmacol 44: 1166-1172, 2004.
13. Twelves CJ: Xeloda in adjuvant colon cancer therapy (X-ACT) trial: overview of efficacy, safety and cost-effectiveness. Clin Colorectal Cancer 6(4): 278-287, 2006.
14. Fujii C, Anami S, Fujino M, et al: Management of hand-foot syndrome in patient treated with capecitabine. Jpn J Cancer Chmother 35(8): 1357-1360, 2008.